Arbutus Biopharma Corporation (ABUS)

[mick]

Arbutus Biopharma (ABUS) Receives a Buy from H.C. Wainwright
August 30 2022 - 11:45AM
TipRanks
Alert
Print
Share On Facebook
In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Arbutus Biopharma (ABUS - Research Report), with a price target of $7.50. The company's shares opened today at $2.33.According to TipRanks, Arce is a 4-star analyst with an average return of 6.6% and a 38.46% success rate. Arce covers the Healthcare sector, focusing on stocks such as Assembly Biosciences, Pliant Therapeutics, and Arbutus Biopharma.The word on The Street in general, suggests a Strong Buy analyst consensus rating for Arbutus Biopharma with a $6.33 average price target.
https://www.tipranks.com/news/blurbs/arbutus-biopharma-abus-receives-a-buy-from-h-c-wainwright-3?utm_source=advfn.com&utm_medium=referral